NVCRNovoCure GmbHFinished
Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)
Nonsmall Cell Lung Cancer · NSCLC
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.7
8 insiders sold shares within a month
Since Jun 4, 2026 · was worth 10, fading over time
Worry score2
Score over time
- Stage
- Phase 3
- Patients
- 291 (final count)
- Started
- Dec 2016
- Main results expected
- Sep 24, 2024
- Fully finished
- Oct 9, 2024
- Results posted
- Mar 18, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Overall Survival of Patients Treated With TTFields + Docetaxel or Immune Checkpoint Inhibitors vs. Docetaxel or Immune Checkpoint Inhibitors Alone (Superiority Analysis)
Measured over: From date of randomization until the date of death from any cause, assessed up to 12 month after the last participant was enrolled (median duration of follow-up was 10.0 months).
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 1.7, since 2026-06-04, fades (half-life)
Raw record changes
- none yet
Trial ID NCT02973789 · record last updated 2026-03-18 · checked 2026-11-09 15:47 UTC